North America Lung Transplant Therapeutics Market is expected to grow with the CAGR of 5.9% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-lung-transplant-therapeutics-market

North America lung transplant therapeutics market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in North America lung transplant therapeutics market are introducing strong range of services portfolio. This helped companies to maximize the sales with enhanced services portfolio.

For instance,

• In July 2021, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for PROGRAF (tacrolimus) for the prevention of organ rejection in adult and pediatric lung transplant recipients.

Astellas Pharma Inc. is dominating player in North America lung transplant therapeutics market. The other key players existing in the market includes Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Panacea Biotech Ltd, Dr, Franz Kohler Chemie GMBH, Dr. Reddy’s laboratories Ltd, Detraxi Inc, Hikma Pharmaceuticals PLC, Apotex Inc., Intas Pharmaceuticals Ltd., Viatris Inc., Bridge to Life Ltd., Transmedics Inc., Paragonix Technologies Inc., Xvivo, OSE Immunotherapeutics, BioLife Solutions, and 21st Century Medicine among others.

ASTELLAS PHARMA INC.

Astellas Pharma Inc was headquartered in Tokyo, Japan and was founded in 2005. The company is engaged in the developments of immunosuppressants. They combine insights from multiple data sources to drive more effective and efficient research and allow for better therapeutic decisions for patients.

• In April 2021, Astellas Pharma Inc. received “2021 Award for Excellence in Corporate Disclosure” from the Securities Analysts Association of Japan. This helped company in strengthening its position over the market, gaining more customer base

The company has presence in Americas, Europe and Asia-Pacific. The company has various subsidiaries that are Astellas Pharma Tech Co.,Ltd(Japan), Astellas Green Supply, Inc.(Japan) , Astellas Pharma US, Inc., Astellas Pharma Canada, Inc., Canada; Astellas U.S Holding Inc. among others

TRANSMEDICS INC.

Transmedics Inc. is headquartered in Burlington, Massachusetts, USA and was founded in year 1995. The company is engaged in products in OCS lung, OCS heart, OCS liver that help lead healthier lives.

• In July 2021, TransMedics had obtained the FDA approval for the OCS Lung Solution used for the cold preservation of lungs. The FDA approval received would result in improvement in product portfolio or organ preservation, and it would meet the unmet clinical needs of the organ transplant market. It would ensure collaborations with market players to supply and meet the customer needs for lung transplantation

The company has wide North America presence across the world as North America.

DR REDDY’S LABORATORIES LTD.

Dr. Reddy’s Laboratories Ltd is headquartered in Telangana, India and was founded in year 1984. The company is engaged in products in gastrointestinal ailments, anti-diabetic, cardiovascular disease, pain management, oncology, anti-infective, pediatrics and dermatology – that help lead healthier lives.

The company has wide North America presence across the world as Europe, Asia-Pacific, Middle East and Africa, Americas a with its subsidiaries such as Aurigene Discovery Technologies (Malaysia) Sdn. Bhd, Dr. Reddy’s Laboratories (Australia) Pty. Limited, Dr. Reddy’s Laboratories (Canada), Inc., Dr. Reddy’s Laboratories (EU), Limited, Dr. Reddy's Laboratories Chile SPA, Dr. Reddy’s Laboratories Japan KK, Dr Reddy’s Laboratories Kazakhstan LLP, Dr. Reddy’s Laboratories New York, LLC, Dr. Reddy's Laboratories (Thailand) Limited, Industrias Quimicas Falcon de Mexico, S.A. de CV among others who are wholly owned subsidiaries.